奥洛他定片剂治疗过敏性鼻炎和荨麻疹的卫生技术评估

Health technology assessment of olopatadine in allergic rhinitis and uticaria

目的:评价奥洛他定治疗过敏性鼻炎与荨麻疹的有效性,安全性与经济性。方法:在Pub Med、Embase、the Cochrane Library、中国知网(CNKI)和万方等数据库中检索"奥洛他定"。结果:研究共纳入随机对照试验(RCT)21篇,其中1篇包含经济性研究,未纳入HTA报告与系统评价(SR)。奥洛他定治疗过敏性鼻炎的有效性优于安慰剂与卢帕他定,优于或不劣于氯雷他定与西替利嗪;治疗荨麻疹的有效性优于卢帕他定和非索非那定,优于或不劣于西替利嗪。与安慰剂、阳性对照药相比,奥洛他定均未增加不良事件发生率。成本效果分析结果显示,相比卢帕他定与非索非那定,奥洛他定经济性占优。结论:奥洛他定治疗过敏性鼻炎与荨麻疹具有良好的有效性与安全性,相比卢帕他定与非索非那定有经济性优势。

Objective： To evaluate the effectiveness,safety and economy of olopatadine while treating allergic rhinitis and uticaria. Methods： Search ＂olopatadine＂in Pub Med,Embase,the Cochrane,China National Knowledge Infrastructure（ CNKI） and Wanfang Database. Results： No health technology assessment（ HTA） or systematic review（ SR） but 21 Randomized controlled trials（ RCTs）,one of which contained economic evaluation,were identified. For the treatment of allergic rhinitis,olopatadine was superior to placebo and rupatadine,superior or not inferior to cetirizine and loratadine. For the treatment of urticaria,olopatadine was superior to placebo,rupatadine,and fexofenadine,and was superior or not inferior to cetirizine and loratadine. Comparing to placebo and positive control drugs, olopatadine did not increase the advertise event rate. Besides, olopatadine had dominance in cost-effectiveness analysis over rupatadine and fexofenadine. Conclusion： Olopatadine showed good efficacy and safety in treating allergic rhinitis as well as uticaria,and had pharmacoeconomics advantage while comparing to rupatadine and fexofenadine.